Skip directly to Accessibility Notice
BBH VanEck Biotech ETF Please read important disclosure Close important disclosure false us en false false

BBH
VanEck Biotech ETF

BBH
VanEck Biotech ETF

  • NAV
    $167.86

    as of May 23, 2024
  • YTD RETURNS
    1.49%

    as of May 23, 2024
  • Total Net Assets
    $440.03M

    as of May 23, 2024
  • Total Expense Ratio
    0.35%
  • Inception Date
    12/20/2011

Fund Description

VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.

Overview

Fund Highlights

  • Highly Liquid Companies 
    Index seeks to track the most liquid companies in the industry based on market cap and trading volume

  • Industry Leaders 
    Index methodology favors the largest companies in the industry

  • Global Scope 
    Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation

Performance

Fees

Holdings

Portfolio

Distributions

Team

Literature

BBH